| Name | Title | Contact Details |
|---|
Founded in 2004, BioRx is a national provider of specialty pharmacy, infusion management and industry consulting services. As a private, independently-owned company, BioRx is committed to a flexible service model that meets the needs of its customers, including consumers, healthcare providers, health plans and pharmaceutical manufacturers. The company’s streamlined management structure allows it to respond more quickly to changes in the marketplace and provide a higher level of service that is customized for each consumer. Moreover, BioRx helps to provide a more cost-effective level of healthcare – in particular by moving patients from costly facility-based infusion sites to their homes, thereby allowing us to closely monitor the administration and outcomes of complex infusion therapies. BioRx consumer services include home delivery of specialty intravenous and injectable pharmaceuticals, medical supplies, nursing support, reimbursement coordination, consumer advocacy, and highly customized care plans. The company also provides professional consulting services to business partners within the insurance and pharmaceutical manufacturing industries.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Hospital Billing and Collection Services is a New Castle, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iHealth Analytics LLC is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Saint Luke Institute is a Silver Spring, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.